Cullen/Frost Bankers, Inc. Neurocrine Biosciences Inc Transaction History

Cullen/Frost Bankers, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$86.91 - $108.33 $521 - $649	-6 Closed	0 $0
Q3 2020 Nov 05, 2020	BUY	$96.16 - $135.15 $576 - $810	6 New	6 $1,000
Q1 2020 May 01, 2020	SELL	$75.11 - $113.76 $6,384 - $9,669	-85 Closed	0 $0
Q4 2019 Feb 06, 2020	SELL	$86.8 - $118.57 $11,718 - $16,006	-135 Reduced 61.36%	85 $9,000
Q3 2019 Nov 01, 2019	BUY	$83.82 - $101.5 $18,440 - $22,330	220 New	220 $20,000

622

95.2M

661K

221K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.